Combined gamma-irradiation and subsequent cisplatin treatment in human squamous carcinoma cell lines sensitive and resistant to cisplatin
Purpose: To investigate the effects of combined radiation and subsequent cisplatin treatment on the human squamous carcinoma cell line SCC-25 and its cisplatin-resistant derivative SCC-25 CP. Materials and methods: SCC-25 and SCC-25 CP cells were treated with various gamma-ray doses (5 cGy-7 Gy) fol...
Gespeichert in:
| Veröffentlicht in: | International journal of radiation biology 2004-04, Vol.80 (4), p.291-299 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 299 |
|---|---|
| container_issue | 4 |
| container_start_page | 291 |
| container_title | International journal of radiation biology |
| container_volume | 80 |
| creator | Caney, C. Singh, G. Lukka, H. Rainbow, A. J. |
| description | Purpose: To investigate the effects of combined radiation and subsequent cisplatin treatment on the human squamous carcinoma cell line SCC-25 and its cisplatin-resistant derivative SCC-25 CP.
Materials and methods: SCC-25 and SCC-25 CP cells were treated with various gamma-ray doses (5 cGy-7 Gy) followed 60 min later by cisplatin treatment and subsequently assayed for survival using a conventional colony assay. For SCC-25, the subsequent cisplatin treatment was 0.1, 1, 10 and 20 µM for 1 h. For the more cisplatin-resistant SCC-25 CP cells, the subsequent cisplatin treatment was 10 and 50 µM for 1 h.
Results: The cisplatin-resistant SCC-25 CP cells were not cross-resistant to gamma-irradiation. Subsequent treatment with an LD50 concentration of cisplatin (10 and 50 µM for SCC-25 and SCC-25 CP, respectively) resulted in radiosensitization for SCC-25 CP but not for SCC-25 cells. Gamma-irradiation of SCC-25 CP cells followed by treatment with 10 and 50 µM cisplatin for 1 h resulted in radiation survival curves displaying a significant low-dose hypersensitive region followed by increased radioresistance at higher doses. A total of 10 µM cisplatin resulted in radiosensitization confined to the low-dose region (0.05 and 0.25 Gy), whereas the higher cisplatin treatment of 50 µM resulted in the appearance of a hypersensitive region together with a reduction of the increased radioresistance region. In contrast, cisplatin treatment (0.1, 1, 10 and 20 µM for 1 h) of SCC-25 cells had no significant effect on survival following 2.5 or 7.0 Gy and actually resulted in an increased low-dose radiation survival (0.05, 0.25 and 1 Gy) when survival was corrected for cisplatin treatment (p |
| doi_str_mv | 10.1080/09553000410001679767 |
| format | Article |
| fullrecord | <record><control><sourceid>informahealthcare_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1080_09553000410001679767</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>10_1080_09553000410001679767</sourcerecordid><originalsourceid>FETCH-LOGICAL-c414t-d2ca9f89e6703abf4dc1ca1f99d13e839f57e6c69ffdaf4db4250c5c85bfdb593</originalsourceid><addsrcrecordid>eNqFkNlKBSEYxyWKOi1vEOELTOk4mzdFHNog6Kauh29cOsaoJ3WKHqG3ztMJIoi6cfsv6g-hQ0qOKenICeF1zQghFc0DbVreNu0GmlHWlAXL4iaarSx5TcodtBvjU_aVhHXbaIfWJala0szQ-9zbwTgl8SNYC4UJAaSBZLzD4CSO0xDV86RcwsLE5ZgVh1NQkOzqLG8WkwWH4_ME1k8RCwjCOG8BCzWOeMzdEUfloknmRX12BhVNTJDjyX-37qMtDWNUB1_zHnq4vLifXxe3d1c38_PbQlS0SoUsBXDdcdW0hMGgKymoAKo5l5SpjnFdt6oRDddaQlaHqqyJqEVXD1oONWd7qFr3iuBjDEr3y2AshLeekn5Ftv-NbI4drWPLabBKfoe-UGbD2dpgnPbBwqsPo-wTvI0-6AAuf7Rn_1xx-qNhoWBMiwxU9U9-Ci5T-fuNH3Fcn24</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Combined gamma-irradiation and subsequent cisplatin treatment in human squamous carcinoma cell lines sensitive and resistant to cisplatin</title><source>MEDLINE</source><source>Taylor & Francis:Master (3349 titles)</source><source>Taylor & Francis Medical Library - CRKN</source><creator>Caney, C. ; Singh, G. ; Lukka, H. ; Rainbow, A. J.</creator><creatorcontrib>Caney, C. ; Singh, G. ; Lukka, H. ; Rainbow, A. J.</creatorcontrib><description>Purpose: To investigate the effects of combined radiation and subsequent cisplatin treatment on the human squamous carcinoma cell line SCC-25 and its cisplatin-resistant derivative SCC-25 CP.
Materials and methods: SCC-25 and SCC-25 CP cells were treated with various gamma-ray doses (5 cGy-7 Gy) followed 60 min later by cisplatin treatment and subsequently assayed for survival using a conventional colony assay. For SCC-25, the subsequent cisplatin treatment was 0.1, 1, 10 and 20 µM for 1 h. For the more cisplatin-resistant SCC-25 CP cells, the subsequent cisplatin treatment was 10 and 50 µM for 1 h.
Results: The cisplatin-resistant SCC-25 CP cells were not cross-resistant to gamma-irradiation. Subsequent treatment with an LD50 concentration of cisplatin (10 and 50 µM for SCC-25 and SCC-25 CP, respectively) resulted in radiosensitization for SCC-25 CP but not for SCC-25 cells. Gamma-irradiation of SCC-25 CP cells followed by treatment with 10 and 50 µM cisplatin for 1 h resulted in radiation survival curves displaying a significant low-dose hypersensitive region followed by increased radioresistance at higher doses. A total of 10 µM cisplatin resulted in radiosensitization confined to the low-dose region (0.05 and 0.25 Gy), whereas the higher cisplatin treatment of 50 µM resulted in the appearance of a hypersensitive region together with a reduction of the increased radioresistance region. In contrast, cisplatin treatment (0.1, 1, 10 and 20 µM for 1 h) of SCC-25 cells had no significant effect on survival following 2.5 or 7.0 Gy and actually resulted in an increased low-dose radiation survival (0.05, 0.25 and 1 Gy) when survival was corrected for cisplatin treatment (p<0.01 for all cisplatin concentrations tested).
Conclusions: The significant radiosensitization for SCC-25 CP given subsequent treatment with 50 µM cisplatin indicates cisplatin can inhibit the increased radioresistance response in SCC-25 CP cells. In contrast, the subsequent cisplatin treatment of SCC-25 cells can enhance their survival following low radiation doses.</description><identifier>ISSN: 0955-3002</identifier><identifier>EISSN: 1362-3095</identifier><identifier>DOI: 10.1080/09553000410001679767</identifier><identifier>PMID: 15204706</identifier><language>eng</language><publisher>England: Informa UK Ltd</publisher><subject>Antineoplastic Agents - pharmacology ; Carcinoma, Squamous Cell - drug therapy ; Carcinoma, Squamous Cell - pathology ; Carcinoma, Squamous Cell - radiotherapy ; Cell Line, Tumor - drug effects ; Cell Line, Tumor - pathology ; Cell Line, Tumor - radiation effects ; Cell Survival - drug effects ; Cell Survival - radiation effects ; Cisplatin - pharmacology ; Combined Modality Therapy ; Dose-Response Relationship, Drug ; Dose-Response Relationship, Radiation ; Drug Resistance, Neoplasm - radiation effects ; Gamma Rays - therapeutic use ; Humans ; Radiation-Sensitizing Agents - pharmacology</subject><ispartof>International journal of radiation biology, 2004-04, Vol.80 (4), p.291-299</ispartof><rights>2004 Informa UK Ltd All rights reserved: reproduction in whole or part not permitted 2004</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c414t-d2ca9f89e6703abf4dc1ca1f99d13e839f57e6c69ffdaf4db4250c5c85bfdb593</citedby><cites>FETCH-LOGICAL-c414t-d2ca9f89e6703abf4dc1ca1f99d13e839f57e6c69ffdaf4db4250c5c85bfdb593</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.tandfonline.com/doi/pdf/10.1080/09553000410001679767$$EPDF$$P50$$Ginformahealthcare$$H</linktopdf><linktohtml>$$Uhttps://www.tandfonline.com/doi/full/10.1080/09553000410001679767$$EHTML$$P50$$Ginformahealthcare$$H</linktohtml><link.rule.ids>314,777,781,27905,27906,59626,59732,60415,60521,61200,61235,61381,61416</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15204706$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Caney, C.</creatorcontrib><creatorcontrib>Singh, G.</creatorcontrib><creatorcontrib>Lukka, H.</creatorcontrib><creatorcontrib>Rainbow, A. J.</creatorcontrib><title>Combined gamma-irradiation and subsequent cisplatin treatment in human squamous carcinoma cell lines sensitive and resistant to cisplatin</title><title>International journal of radiation biology</title><addtitle>Int J Radiat Biol</addtitle><description>Purpose: To investigate the effects of combined radiation and subsequent cisplatin treatment on the human squamous carcinoma cell line SCC-25 and its cisplatin-resistant derivative SCC-25 CP.
Materials and methods: SCC-25 and SCC-25 CP cells were treated with various gamma-ray doses (5 cGy-7 Gy) followed 60 min later by cisplatin treatment and subsequently assayed for survival using a conventional colony assay. For SCC-25, the subsequent cisplatin treatment was 0.1, 1, 10 and 20 µM for 1 h. For the more cisplatin-resistant SCC-25 CP cells, the subsequent cisplatin treatment was 10 and 50 µM for 1 h.
Results: The cisplatin-resistant SCC-25 CP cells were not cross-resistant to gamma-irradiation. Subsequent treatment with an LD50 concentration of cisplatin (10 and 50 µM for SCC-25 and SCC-25 CP, respectively) resulted in radiosensitization for SCC-25 CP but not for SCC-25 cells. Gamma-irradiation of SCC-25 CP cells followed by treatment with 10 and 50 µM cisplatin for 1 h resulted in radiation survival curves displaying a significant low-dose hypersensitive region followed by increased radioresistance at higher doses. A total of 10 µM cisplatin resulted in radiosensitization confined to the low-dose region (0.05 and 0.25 Gy), whereas the higher cisplatin treatment of 50 µM resulted in the appearance of a hypersensitive region together with a reduction of the increased radioresistance region. In contrast, cisplatin treatment (0.1, 1, 10 and 20 µM for 1 h) of SCC-25 cells had no significant effect on survival following 2.5 or 7.0 Gy and actually resulted in an increased low-dose radiation survival (0.05, 0.25 and 1 Gy) when survival was corrected for cisplatin treatment (p<0.01 for all cisplatin concentrations tested).
Conclusions: The significant radiosensitization for SCC-25 CP given subsequent treatment with 50 µM cisplatin indicates cisplatin can inhibit the increased radioresistance response in SCC-25 CP cells. In contrast, the subsequent cisplatin treatment of SCC-25 cells can enhance their survival following low radiation doses.</description><subject>Antineoplastic Agents - pharmacology</subject><subject>Carcinoma, Squamous Cell - drug therapy</subject><subject>Carcinoma, Squamous Cell - pathology</subject><subject>Carcinoma, Squamous Cell - radiotherapy</subject><subject>Cell Line, Tumor - drug effects</subject><subject>Cell Line, Tumor - pathology</subject><subject>Cell Line, Tumor - radiation effects</subject><subject>Cell Survival - drug effects</subject><subject>Cell Survival - radiation effects</subject><subject>Cisplatin - pharmacology</subject><subject>Combined Modality Therapy</subject><subject>Dose-Response Relationship, Drug</subject><subject>Dose-Response Relationship, Radiation</subject><subject>Drug Resistance, Neoplasm - radiation effects</subject><subject>Gamma Rays - therapeutic use</subject><subject>Humans</subject><subject>Radiation-Sensitizing Agents - pharmacology</subject><issn>0955-3002</issn><issn>1362-3095</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkNlKBSEYxyWKOi1vEOELTOk4mzdFHNog6Kauh29cOsaoJ3WKHqG3ztMJIoi6cfsv6g-hQ0qOKenICeF1zQghFc0DbVreNu0GmlHWlAXL4iaarSx5TcodtBvjU_aVhHXbaIfWJala0szQ-9zbwTgl8SNYC4UJAaSBZLzD4CSO0xDV86RcwsLE5ZgVh1NQkOzqLG8WkwWH4_ME1k8RCwjCOG8BCzWOeMzdEUfloknmRX12BhVNTJDjyX-37qMtDWNUB1_zHnq4vLifXxe3d1c38_PbQlS0SoUsBXDdcdW0hMGgKymoAKo5l5SpjnFdt6oRDddaQlaHqqyJqEVXD1oONWd7qFr3iuBjDEr3y2AshLeekn5Ftv-NbI4drWPLabBKfoe-UGbD2dpgnPbBwqsPo-wTvI0-6AAuf7Rn_1xx-qNhoWBMiwxU9U9-Ci5T-fuNH3Fcn24</recordid><startdate>200404</startdate><enddate>200404</enddate><creator>Caney, C.</creator><creator>Singh, G.</creator><creator>Lukka, H.</creator><creator>Rainbow, A. J.</creator><general>Informa UK Ltd</general><general>Taylor & Francis</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>200404</creationdate><title>Combined gamma-irradiation and subsequent cisplatin treatment in human squamous carcinoma cell lines sensitive and resistant to cisplatin</title><author>Caney, C. ; Singh, G. ; Lukka, H. ; Rainbow, A. J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c414t-d2ca9f89e6703abf4dc1ca1f99d13e839f57e6c69ffdaf4db4250c5c85bfdb593</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Antineoplastic Agents - pharmacology</topic><topic>Carcinoma, Squamous Cell - drug therapy</topic><topic>Carcinoma, Squamous Cell - pathology</topic><topic>Carcinoma, Squamous Cell - radiotherapy</topic><topic>Cell Line, Tumor - drug effects</topic><topic>Cell Line, Tumor - pathology</topic><topic>Cell Line, Tumor - radiation effects</topic><topic>Cell Survival - drug effects</topic><topic>Cell Survival - radiation effects</topic><topic>Cisplatin - pharmacology</topic><topic>Combined Modality Therapy</topic><topic>Dose-Response Relationship, Drug</topic><topic>Dose-Response Relationship, Radiation</topic><topic>Drug Resistance, Neoplasm - radiation effects</topic><topic>Gamma Rays - therapeutic use</topic><topic>Humans</topic><topic>Radiation-Sensitizing Agents - pharmacology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Caney, C.</creatorcontrib><creatorcontrib>Singh, G.</creatorcontrib><creatorcontrib>Lukka, H.</creatorcontrib><creatorcontrib>Rainbow, A. J.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>International journal of radiation biology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Caney, C.</au><au>Singh, G.</au><au>Lukka, H.</au><au>Rainbow, A. J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Combined gamma-irradiation and subsequent cisplatin treatment in human squamous carcinoma cell lines sensitive and resistant to cisplatin</atitle><jtitle>International journal of radiation biology</jtitle><addtitle>Int J Radiat Biol</addtitle><date>2004-04</date><risdate>2004</risdate><volume>80</volume><issue>4</issue><spage>291</spage><epage>299</epage><pages>291-299</pages><issn>0955-3002</issn><eissn>1362-3095</eissn><abstract>Purpose: To investigate the effects of combined radiation and subsequent cisplatin treatment on the human squamous carcinoma cell line SCC-25 and its cisplatin-resistant derivative SCC-25 CP.
Materials and methods: SCC-25 and SCC-25 CP cells were treated with various gamma-ray doses (5 cGy-7 Gy) followed 60 min later by cisplatin treatment and subsequently assayed for survival using a conventional colony assay. For SCC-25, the subsequent cisplatin treatment was 0.1, 1, 10 and 20 µM for 1 h. For the more cisplatin-resistant SCC-25 CP cells, the subsequent cisplatin treatment was 10 and 50 µM for 1 h.
Results: The cisplatin-resistant SCC-25 CP cells were not cross-resistant to gamma-irradiation. Subsequent treatment with an LD50 concentration of cisplatin (10 and 50 µM for SCC-25 and SCC-25 CP, respectively) resulted in radiosensitization for SCC-25 CP but not for SCC-25 cells. Gamma-irradiation of SCC-25 CP cells followed by treatment with 10 and 50 µM cisplatin for 1 h resulted in radiation survival curves displaying a significant low-dose hypersensitive region followed by increased radioresistance at higher doses. A total of 10 µM cisplatin resulted in radiosensitization confined to the low-dose region (0.05 and 0.25 Gy), whereas the higher cisplatin treatment of 50 µM resulted in the appearance of a hypersensitive region together with a reduction of the increased radioresistance region. In contrast, cisplatin treatment (0.1, 1, 10 and 20 µM for 1 h) of SCC-25 cells had no significant effect on survival following 2.5 or 7.0 Gy and actually resulted in an increased low-dose radiation survival (0.05, 0.25 and 1 Gy) when survival was corrected for cisplatin treatment (p<0.01 for all cisplatin concentrations tested).
Conclusions: The significant radiosensitization for SCC-25 CP given subsequent treatment with 50 µM cisplatin indicates cisplatin can inhibit the increased radioresistance response in SCC-25 CP cells. In contrast, the subsequent cisplatin treatment of SCC-25 cells can enhance their survival following low radiation doses.</abstract><cop>England</cop><pub>Informa UK Ltd</pub><pmid>15204706</pmid><doi>10.1080/09553000410001679767</doi><tpages>9</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0955-3002 |
| ispartof | International journal of radiation biology, 2004-04, Vol.80 (4), p.291-299 |
| issn | 0955-3002 1362-3095 |
| language | eng |
| recordid | cdi_crossref_primary_10_1080_09553000410001679767 |
| source | MEDLINE; Taylor & Francis:Master (3349 titles); Taylor & Francis Medical Library - CRKN |
| subjects | Antineoplastic Agents - pharmacology Carcinoma, Squamous Cell - drug therapy Carcinoma, Squamous Cell - pathology Carcinoma, Squamous Cell - radiotherapy Cell Line, Tumor - drug effects Cell Line, Tumor - pathology Cell Line, Tumor - radiation effects Cell Survival - drug effects Cell Survival - radiation effects Cisplatin - pharmacology Combined Modality Therapy Dose-Response Relationship, Drug Dose-Response Relationship, Radiation Drug Resistance, Neoplasm - radiation effects Gamma Rays - therapeutic use Humans Radiation-Sensitizing Agents - pharmacology |
| title | Combined gamma-irradiation and subsequent cisplatin treatment in human squamous carcinoma cell lines sensitive and resistant to cisplatin |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-18T03%3A13%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-informahealthcare_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Combined%20gamma-irradiation%20and%20subsequent%20cisplatin%20treatment%20in%20human%20squamous%20carcinoma%20cell%20lines%20sensitive%20and%20resistant%20to%20cisplatin&rft.jtitle=International%20journal%20of%20radiation%20biology&rft.au=Caney,%20C.&rft.date=2004-04&rft.volume=80&rft.issue=4&rft.spage=291&rft.epage=299&rft.pages=291-299&rft.issn=0955-3002&rft.eissn=1362-3095&rft_id=info:doi/10.1080/09553000410001679767&rft_dat=%3Cinformahealthcare_cross%3E10_1080_09553000410001679767%3C/informahealthcare_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/15204706&rfr_iscdi=true |